Skip to main content
PMC home page
Genitourinary Medicine logoLink to Genitourinary Medicine
. 1996 Aug;72(4):237–246. doi: 10.1136/sti.72.4.237

Adverse effects and drug interactions of medications commonly used in the treatment of adult HIV positive patients.

R Heylen 1, R Miller 1
PMCID: PMC1195670  PMID: 8976826

Full text

PDF
237

Images in this article

244Image
on p.244
240Image
on p.240
242Image
on p.242
238Image
on p.238

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albani F., Riva R., Baruzzi A. Clarithromycin-carbamazepine interaction: a case report. Epilepsia. 1993 Jan-Feb;34(1):161–162. doi: 10.1111/j.1528-1157.1993.tb02391.x. [DOI] [PubMed] [Google Scholar]
  2. Antoniskis D., Larsen R. A. Acute, rapidly progressive renal failure with simultaneous use of amphotericin B and pentamidine. Antimicrob Agents Chemother. 1990 Mar;34(3):470–472. doi: 10.1128/aac.34.3.470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Asgari M., Back D. J. Effect of azoles on the glucuronidation of zidovudine by human liver UDP-glucuronosyltransferase. J Infect Dis. 1995 Dec;172(6):1634–1636. doi: 10.1093/infdis/172.6.1634. [DOI] [PubMed] [Google Scholar]
  4. Bach M. C. Possible drug interaction during therapy with azidothymidine and acyclovir for AIDS. N Engl J Med. 1987 Feb 26;316(9):547–547. doi: 10.1056/NEJM198702263160912. [DOI] [PubMed] [Google Scholar]
  5. Ballow C. H., Amsden G. W. Azithromycin: the first azalide antibiotic. Ann Pharmacother. 1992 Oct;26(10):1253–1261. doi: 10.1177/106002809202601014. [DOI] [PubMed] [Google Scholar]
  6. Blomley M., Teare E. L., de Belder A., Thway Y., Weston M. Itraconazole and anti-tuberculosis drugs. Lancet. 1990 Nov 17;336(8725):1255–1255. doi: 10.1016/0140-6736(90)92873-g. [DOI] [PubMed] [Google Scholar]
  7. Blum M. R., Liao S. H., Good S. S., de Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med. 1988 Aug 29;85(2A):189–194. [PubMed] [Google Scholar]
  8. Blum R. A., D'Andrea D. T., Florentino B. M., Wilton J. H., Hilligoss D. M., Gardner M. J., Henry E. B., Goldstein H., Schentag J. J. Increased gastric pH and the bioavailability of fluconazole and ketoconazole. Ann Intern Med. 1991 May 1;114(9):755–757. doi: 10.7326/0003-4819-114-9-755. [DOI] [PubMed] [Google Scholar]
  9. Bonay M., Jonville-Bera A. P., Diot P., Lemarie E., Lavandier M., Autret E. Possible interaction between phenobarbital, carbamazepine and itraconazole. Drug Saf. 1993 Oct;9(4):309–311. doi: 10.2165/00002018-199309040-00008. [DOI] [PubMed] [Google Scholar]
  10. Buffington G. A., Dominguez J. H., Piering W. F., Hebert L. A., Kauffman H. M., Jr, Lemann J., Jr Interaction of rifampin and glucocorticoids. Adverse effect on renal allograft function. JAMA. 1976 Oct 25;236(17):1958–1960. [PubMed] [Google Scholar]
  11. Burger D. M., Meenhorst P. L., Koks C. H., Beijnen J. H. Pharmacokinetics of zidovudine and acetaminophen in a patient on chronic acetaminophen therapy. Ann Pharmacother. 1994 Mar;28(3):327–330. doi: 10.1177/106002809402800306. [DOI] [PubMed] [Google Scholar]
  12. Böhme A., Ganser A., Hoelzer D. Aggravation of vincristine-induced neurotoxicity by itraconazole in the treatment of adult ALL. Ann Hematol. 1995 Dec;71(6):311–312. doi: 10.1007/BF01697985. [DOI] [PubMed] [Google Scholar]
  13. Cadle R. M., Zenon G. J., 3rd, Rodriguez-Barradas M. C., Hamill R. J. Fluconazole-induced symptomatic phenytoin toxicity. Ann Pharmacother. 1994 Feb;28(2):191–195. doi: 10.1177/106002809402800206. [DOI] [PubMed] [Google Scholar]
  14. Caplin M., Thompson N., Hamilton M., McIntyre N., Burroughs A. Antituberculous therapy and acute liver failure. Lancet. 1995 May 6;345(8958):1171–1171. [PubMed] [Google Scholar]
  15. Coker R. J., Tomlinson D. R., Parkin J., Harris J. R., Pinching A. J. Interaction between fluconazole and rifampicin. BMJ. 1990 Oct 6;301(6755):818–818. doi: 10.1136/bmj.301.6755.818. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Cundy K. C., Petty B. G., Flaherty J., Fisher P. E., Polis M. A., Wachsman M., Lietman P. S., Lalezari J. P., Hitchcock M. J., Jaffe H. S. Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. Antimicrob Agents Chemother. 1995 Jun;39(6):1247–1252. doi: 10.1128/aac.39.6.1247. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Drayton J., Dickinson G., Rinaldi M. G. Coadministration of rifampin and itraconazole leads to undetectable levels of serum itraconazole. Clin Infect Dis. 1994 Feb;18(2):266–266. doi: 10.1093/clinids/18.2.266. [DOI] [PubMed] [Google Scholar]
  18. Dudley M. N., Graham K. K., Kaul S., Geletko S., Dunkle L., Browne M., Mayer K. Pharmacokinetics of stavudine in patients with AIDS or AIDS-related complex. J Infect Dis. 1992 Sep;166(3):480–485. doi: 10.1093/infdis/166.3.480. [DOI] [PubMed] [Google Scholar]
  19. Fan-Harvard P., Sanchorawala V., Oh J., Moser E. M., Smith S. P. Concurrent use of foscarnet and ciprofloxacin may increase the propensity for seizures. Ann Pharmacother. 1994 Jul-Aug;28(7-8):869–872. doi: 10.1177/106002809402800708. [DOI] [PubMed] [Google Scholar]
  20. Fischl M. A., Richman D. D., Grieco M. H., Gottlieb M. S., Volberding P. A., Laskin O. L., Leedom J. M., Groopman J. E., Mildvan D., Schooley R. T. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987 Jul 23;317(4):185–191. doi: 10.1056/NEJM198707233170401. [DOI] [PubMed] [Google Scholar]
  21. Frank M. O., Graham M. B., Wispelway B. Rifabutin and uveitis. N Engl J Med. 1994 Mar 24;330(12):868–868. doi: 10.1056/NEJM199403243301218. [DOI] [PubMed] [Google Scholar]
  22. Fuller J. D., Stanfield L. E., Craven D. E. Rifabutin prophylaxis and uveitis. N Engl J Med. 1994 May 5;330(18):1315–1316. doi: 10.1056/NEJM199405053301816. [DOI] [PubMed] [Google Scholar]
  23. Griffith D. E., Brown B. A., Girard W. M., Wallace R. J., Jr Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease. Clin Infect Dis. 1995 Sep;21(3):594–598. doi: 10.1093/clinids/21.3.594. [DOI] [PubMed] [Google Scholar]
  24. Hochster H., Dieterich D., Bozzette S., Reichman R. C., Connor J. D., Liebes L., Sonke R. L., Spector S. A., Valentine F., Pettinelli C. Toxicity of combined ganciclovir and zidovudine for cytomegalovirus disease associated with AIDS. An AIDS Clinical Trials Group Study. Ann Intern Med. 1990 Jul 15;113(2):111–117. doi: 10.7326/0003-4819-113-2-111. [DOI] [PubMed] [Google Scholar]
  25. Honig P. K., Wortham D. C., Hull R., Zamani K., Smith J. E., Cantilena L. R. Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmacodynamics. J Clin Pharmacol. 1993 Dec;33(12):1201–1206. doi: 10.1002/j.1552-4604.1993.tb03920.x. [DOI] [PubMed] [Google Scholar]
  26. Horowitz H. W., Jorde U. P., Wormser G. P. Drug interactions in use of dapsone for Pneumocystis carinii prophylaxis. Lancet. 1992 Mar 21;339(8795):747–747. doi: 10.1016/0140-6736(92)90649-n. [DOI] [PubMed] [Google Scholar]
  27. Hughes W., Leoung G., Kramer F., Bozzette S. A., Safrin S., Frame P., Clumeck N., Masur H., Lancaster D., Chan C. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med. 1993 May 27;328(21):1521–1527. doi: 10.1056/NEJM199305273282103. [DOI] [PubMed] [Google Scholar]
  28. Israelski D. M., Tom C., Remington J. S. Zidovudine antagonizes the action of pyrimethamine in experimental infection with Toxoplasma gondii. Antimicrob Agents Chemother. 1989 Jan;33(1):30–34. doi: 10.1128/aac.33.1.30. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Jacobson M. A., Yajko D., Northfelt D., Charlebois E., Gary D., Brosgart C., Sanders C. A., Hadley W. K. Randomized, placebo-controlled trial of rifampin, ethambutol, and ciprofloxacin for AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis. 1993 Jul;168(1):112–119. doi: 10.1093/infdis/168.1.112. [DOI] [PubMed] [Google Scholar]
  30. Jacobson M. A., de Miranda P., Cederberg D. M., Burnette T., Cobb E., Brodie H. R., Mills J. Human pharmacokinetics and tolerance of oral ganciclovir. Antimicrob Agents Chemother. 1987 Aug;31(8):1251–1254. doi: 10.1128/aac.31.8.1251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Metroka C. E., McMechan M. F., Andrada R., Laubenstein L. J., Jacobus D. P. Failure of prophylaxis with dapsone in patients taking dideoxyinosine. N Engl J Med. 1991 Sep 5;325(10):737–737. doi: 10.1056/nejm199109053251014. [DOI] [PubMed] [Google Scholar]
  32. Narang P. K., Trapnell C. B., Schoenfelder J. R., Lavelle J. P., Bianchine J. R. Fluconazole and enhanced effect of rifabutin prophylaxis. N Engl J Med. 1994 May 5;330(18):1316–1317. doi: 10.1056/NEJM199405053301817. [DOI] [PubMed] [Google Scholar]
  33. Nicolau D. P., Crowe H. M., Nightingale C. H., Quintiliani R. Rifampin-fluconazole interaction in critically ill patients. Ann Pharmacother. 1995 Oct;29(10):994–996. doi: 10.1177/106002809502901007. [DOI] [PubMed] [Google Scholar]
  34. Nightingale S. D., Cameron D. W., Gordin F. M., Sullam P. M., Cohn D. L., Chaisson R. E., Eron L. J., Sparti P. D., Bihari B., Kaufman D. L. Two controlled trials of rifabutin prophylaxis against Mycobacterium avium complex infection in AIDS. N Engl J Med. 1993 Sep 16;329(12):828–833. doi: 10.1056/NEJM199309163291202. [DOI] [PubMed] [Google Scholar]
  35. Olkkola K. T., Backman J. T., Neuvonen P. J. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994 May;55(5):481–485. doi: 10.1038/clpt.1994.60. [DOI] [PubMed] [Google Scholar]
  36. Pahls S., Schaffner A. Aspergillus fumigatus pneumonia in neutropenic patients receiving fluconazole for infection due to Candida species: is amphotericin B combined with fluconazole the appropriate answer? Clin Infect Dis. 1994 Mar;18(3):484–486. doi: 10.1093/clinids/18.3.484. [DOI] [PubMed] [Google Scholar]
  37. Palestine A. G., Polis M. A., De Smet M. D., Baird B. F., Falloon J., Kovacs J. A., Davey R. T., Zurlo J. J., Zunich K. M., Davis M. A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. Ann Intern Med. 1991 Nov 1;115(9):665–673. doi: 10.7326/0003-4819-115-9-665. [DOI] [PubMed] [Google Scholar]
  38. Pessayre D., Larrey D., Funck-Brentano C., Benhamou J. P. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother. 1985 Jul;16 (Suppl A):181–194. doi: 10.1093/jac/16.suppl_a.181. [DOI] [PubMed] [Google Scholar]
  39. Sandström E., Oberg B. Antiviral therapy in human immunodeficiency virus infections. Current status (Part I). Drugs. 1993 Apr;45(4):488–508. doi: 10.2165/00003495-199345040-00002. [DOI] [PubMed] [Google Scholar]
  40. Scheven M., Scheven M. L. Interaction between azoles and amphotericin B in the treatment of candidiasis. Clin Infect Dis. 1995 Apr;20(4):1079–1079. doi: 10.1093/clinids/20.4.1079. [DOI] [PubMed] [Google Scholar]
  41. Schwartz E. L., Brechbühl A. B., Kahl P., Miller M. A., Selwyn P. A., Friedland G. H. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection. J Acquir Immune Defic Syndr. 1992;5(6):619–626. [PubMed] [Google Scholar]
  42. Seaton T. L., Celum C. L., Black D. J. Possible potentiation of warfarin by fluconazole. DICP. 1990 Dec;24(12):1177–1178. doi: 10.1177/106002809002401207. [DOI] [PubMed] [Google Scholar]
  43. Shriner K., Goetz M. B. Severe hepatotoxicity in a patient receiving both acetaminophen and zidovudine. Am J Med. 1992 Jul;93(1):94–96. doi: 10.1016/0002-9343(92)90687-7. [DOI] [PubMed] [Google Scholar]
  44. Siegal F. P., Eilbott D., Burger H., Gehan K., Davidson B., Kaell A. T., Weiser B. Dose-limiting toxicity of rifabutin in AIDS-related complex: syndrome of arthralgia/arthritis. AIDS. 1990 May;4(5):433–441. doi: 10.1097/00002030-199005000-00009. [DOI] [PubMed] [Google Scholar]
  45. Sjövall J., Bergdahl S., Movin G., Ogenstad S., Saarimäki M. Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. Antimicrob Agents Chemother. 1989 Jul;33(7):1023–1031. doi: 10.1128/aac.33.7.1023. [DOI] [PMC free article] [PubMed] [Google Scholar]
  46. Steffe E. M., King J. H., Inciardi J. F., Flynn N. F., Goldstein E., Tonjes T. S., Benet L. Z. The effect of acetaminophen on zidovudine metabolism in HIV-infected patients. J Acquir Immune Defic Syndr. 1990;3(7):691–694. [PubMed] [Google Scholar]
  47. Sugar E. F., Sugar A. M., Kreger B. E. Effect of various common beverages on the dissolution of ketoconazole tablets. AIDS. 1992 Oct;6(10):1221–1222. doi: 10.1097/00002030-199210000-00030. [DOI] [PubMed] [Google Scholar]
  48. Tobe S. W., Siu L. L., Jamal S. A., Skorecki K. L., Murphy G. F., Warner E. Vinblastine and erythromycin: an unrecognized serious drug interaction. Cancer Chemother Pharmacol. 1995;35(3):188–190. doi: 10.1007/BF00686546. [DOI] [PubMed] [Google Scholar]
  49. Vance E., Watson-Bitar M., Gustavson L., Kazanjian P. Pharmacokinetics of clarithromycin and zidovudine in patients with AIDS. Antimicrob Agents Chemother. 1995 Jun;39(6):1355–1360. doi: 10.1128/aac.39.6.1355. [DOI] [PMC free article] [PubMed] [Google Scholar]
  50. Wallace R. J., Jr, Brown B. A., Griffith D. E., Girard W., Tanaka K. Reduced serum levels of clarithromycin in patients treated with multidrug regimens including rifampin or rifabutin for Mycobacterium avium-M. intracellulare infection. J Infect Dis. 1995 Mar;171(3):747–750. doi: 10.1093/infdis/171.3.747. [DOI] [PubMed] [Google Scholar]
  51. de Miranda P., Blum M. R. Pharmacokinetics of acyclovir after intravenous and oral administration. J Antimicrob Chemother. 1983 Sep;12 (Suppl B):29–37. doi: 10.1093/jac/12.suppl_b.29. [DOI] [PubMed] [Google Scholar]

Articles from Genitourinary Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES